SOPHiA GENETICS, in collaboration with AstraZeneca, conducted a study that leveraged advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who ...
Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
Myriad Genetics, Inc. announced its preliminary financial results for the fourth quarter and full year of 2024, projecting total revenues of $209 million to $211 million for Q4 and $836 million to ...
Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode. After the ...
Good morning. My name is Nicole [ph] and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS Third Quarter 2024 Earnings Conference Call. At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results